{
  "id": 14481996,
  "title": "MaxCyte stock surges 25% on raised 2026 revenue guidance",
  "url": "https://urgent.news/2026/10/14/maxcyte-stock-surges-25-on-raised-2026-revenue-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T16:00:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/maxcyte-stock-surges-25-on-raised-2026-revenue-guidance-4949732"
  },
  "original_language": "en",
  "account": null,
  "summary": "MaxCyte Inc (NASDAQ:MXCT) shares experienced a 25% surge following the cell-engineering company's announcement of raised full-year 2026 revenue guidance. The company reported a strong third-quarter performance, with core business revenue reaching approximately $8.1 million, marking a 26% year-over-year increase. MaxCyte also recorded Strategic Platform License Program-related revenue of over $1.0 million, including a $1.0 million milestone payment. The company raised its full-year 2026 revenue guidance to around $34 million, surpassing the previous estimate of $31.45 million. This growth is attributed to accelerated instrument purchasing from a major customer and the expansion of late-stage clinical programs under its Strategic Platform License partnerships. The updated guidance indicates a 15% year-over-year growth in core business revenue for the second half of 2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}